Not all honey is created equal. That statement, once dismissed as marketing language, is now well-supported by peer-reviewed chemistry. Manuka honey is produced by bees foraging on Leptospermum scoparium, a flowering shrub native to New Zealand and south-eastern...
Obesity care is at a turning point. GLP-1s like Ozempic and Mounjaro have upended weight loss culture – and the research backs them up. For the first time, multiple randomized trials have found that anti-obesity medications can lead to an average 15-20% weight loss....
Pharma generates more insight than ever. Translating that insight into timely action is where the system falters, and the gap runs deeper than most commercial leaders are willing to admit. Over the past decade, omnichannel systems have matured considerably. CRM...
The biopharma industry is at an inflection point as it enters 2026. Discoveries from the past year will be applied and scaled, particularly across AI-enabled drug development, advanced modalities and cardiometabolic disease treatment. These advancements will occur...
GLP-1 medications have changed the landscape of weight management. For many people, they have delivered clinically meaningful weight loss alongside improvements in glycaemic control, and their place in treatment pathways is now well established. What is becoming...
Against a backdrop of rising development and launch costs, growing regulatory complexity, geopolitical uncertainty and intensifying competition for specialist talent, many European pharma and biotech companies are reassessing the long-held ambition of “cracking the...
Against a backdrop of rising development and launch costs, growing regulatory complexity, geopolitical uncertainty and intensifying competition for specialist talent, many European pharma and biotech companies are reassessing the long-held ambition of “cracking the...
Johnson & Johnson has announced plans to invest more than $1 billion in a new cell therapy manufacturing facility in Montgomery County, Pennsylvania. This project marks a significant expansion of its advanced therapies infrastructure and reinforces the company’s...
In the last decade, the Medical Science Liaison role has evolved from a scientific messenger to a field based strategist operating in one of the most highly scrutinized environments in healthcare. That evolution is why board certification is moving from optional...
NICE recommends life-extending daily pill which offers hope for people who cannot take standard treatment. Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23...
Novo Nordisk and Aspect Biosystems expand collaboration to accelerate curative diabetes therapies The landscape of regenerative medicine has shifted significantly following the announcement that Novo Nordisk and Aspect Biosystems are entering a comprehensive new phase...
GSK has agreed to acquire US biotech company RAPT Therapeutics in a deal valued at approximately 2.2 billion US dollars, strengthening its position in immunology and signalling a major push into the emerging food allergy treatment market. The acquisition centres on...
We all know or work with people who can be difficult to deal with and even talk to, and we all know or work with other people who are a joy to be around and who make the working day a little brighter. Some of those difficult people will be highly competent in their...
Metformin has been the first line drug treatment for type 2 diabetes for more than two decades and remains one of the most widely prescribed medicines globally. Its effectiveness, low cost and long safety record have made it a cornerstone of diabetes care. However, as...
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...
Johnson & Johnson has discontinued development of an eczema treatment that was a central asset in a biotechnology acquisition valued at up to 1.25 billion US dollars, following a recent internal portfolio review. The decision highlights the ongoing scientific and...
Concerns are mounting that the United Kingdom’s official appraisal framework is systematically underestimating the economic and social value of investments in life sciences manufacturing. Industry bodies and independent analysts warn that the methods used to evaluate...
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...